Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 8,249 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Completed Phase 1 Interventional

A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission

NCT01632852
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
CSL362
Biological
Lead sponsor
CSL Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

NCT00968071
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
Decitabine, Gemtuzumab Ozogamicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sitting Interruption and Whole-body Cardiovascular Health

NCT05316571
View directory record Official record
Conditions
Sedentary Behavior, Sedentary Time
Interventions
One 5-Minute Walking Bout Each Hour, One 15-Minute Standing Bout Each Hour, One 5-Minute Walking Bout and One 15-Minute Standing Bout Each Hour, Uninterrupted Sitting
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 60 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protocol for High-Risk Assessment, Screening, and Early Detection of Pancreatic Cancer

NCT01662609
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Endoscopic Ultrasound (EUS)
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
30 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2022
U.S. locations
2
States / cities
Tampa, Florida • Allentown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

NCT00619099
View directory record Official record
Conditions
Myelodysplastic Syndrome
Interventions
decitabine
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
4
States / cities
Canton, Ohio • Woonsocket, Rhode Island • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2013 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ALateral Flow Assay to Detect QSOX1 Peptide in Patients With or at Risk for Pancreatic Cancer

NCT04064034
View directory record Official record
Conditions
Pancreas Cancer, Pancreas Cyst
Interventions
Lateral Flow Assay (LFA)
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
17 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

NCT00671034
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
Interventions
Calaspargase Pegol-mknl, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Pegaspargase, Pharmacological Study, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 30 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • Palo Alto, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 3 Interventional Results available

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

NCT04175834
View directory record Official record
Conditions
Multiple Sclerosis, Infusion Reaction
Interventions
cetrizine, diphenhydramine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 23, 2026, 8:01 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

NCT03033914
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
9
States / cities
Detroit, Michigan • Basking Ridge, New Jersey • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Translation Study of a Safe Teen Driving Intervention

NCT04317547
View directory record Official record
Conditions
Drive, Adolescent Behavior, Risk Behavior
Interventions
Steering Teens Safe (STS), Driving Feedback Technology.
Behavioral
Lead sponsor
Ginger Yang
Other
Eligibility
16 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 22, 2024 · Synced Oct 23, 2026, 8:01 PM EDT
Active, not recruiting Not applicable Interventional

Pivotal, Prospective, Multi-centre, Single-arm Study to Evaluate the Safety and Effectiveness of Oli for Identification of Patients, During the Intrapartum Period, Who Are at Higher Risk of Developing Abnormal Postpartum Uterine Bleeding, Including Postpartum Haemorrhage

NCT06655207
View directory record Official record
Conditions
Post Partum Haemorrhage, Maternal Care Patterns, High Risk Pregnancy
Interventions
Oli is a non-invasive, wearable device, designed to provide clinicians with an early indication if the participant is at a higher risk of developing abnormal postpartum uterine bleeding
Device
Lead sponsor
Baymatob Operations Pty Ltd
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Denver, Colorado • Baton Rouge, Louisiana • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Music-Based Interventions, Aging, Alzheimer's Disease

NCT06152211
View directory record Official record
Conditions
Speech Perception, Anxiety, Social Behavior
Interventions
Choir, Group Music Listening
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
65 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 23, 2026, 8:01 PM EDT
Terminated Early Phase 1 Interventional

HCL Single Arm Pilot Study in Treatment of Hyperglycemia of Pediatric ALL

NCT05006040
View directory record Official record
Conditions
High Risk Acute Lymphoblastic Leukemia
Interventions
Hybrid Closed Loop System
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
10 Years to 26 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 23, 2026, 8:01 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Growing Healthy Hearts: A Pilot Randomized Control Trial to Test Gardening as an Intervention to Improve Health

NCT04207268
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Gardening and Nutrition Advice, Nutrition Advice
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
20 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 23, 2026, 8:01 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Summertime: Kids in Motion

NCT03947918
View directory record Official record
Conditions
Sleep
Interventions
Short sleep, Long sleep
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
8 Years to 10 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2025 · Synced Oct 23, 2026, 8:01 PM EDT
Not listed Not applicable Interventional

INcreasing Statin Prescribing in HIV Behavioral Economics REsearch

NCT03687060
View directory record Official record
Conditions
HIV, Cardiovascular Diseases
Interventions
Knowledge assessment, Education Intervention, Provider Feedback
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
40 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Commerce, California • Lancaster, California • Los Angeles, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 8:01 PM EDT
Not listed Early Phase 1 Interventional

Use of Impedance Cardiography to Decrease the Risk of Pre-eclampsia in Obese Patients

NCT03105661
View directory record Official record
Conditions
Obesity, Morbid, Preeclampsia
Interventions
Labetalol Hydrochloride 200 mg, NIFEdipine 60 mg, Atenolol 25 mg
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 51 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional Results available

Screening Brief Intervention Referral to Treatment (SBIRT) in New Mexico

NCT01131520
View directory record Official record
Conditions
Drug Abuse, HIV Risk Behavior
Interventions
Computerized brief intervention, Counselor delivered brief intervention
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia

NCT00003659
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, rituximab, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Not applicable Interventional

Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer

NCT00296023
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 1 Interventional

Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT00101296
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions
tipifarnib, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 23, 2026, 8:01 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 8:01 PM EDT
Active, not recruiting Phase 2 Interventional

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

NCT03363373
View directory record Official record
Conditions
Neuroblastoma
Interventions
GM-CSF + Naxitamab
Biological
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
1 Year and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
Indianapolis, Indiana • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 23, 2026, 8:01 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Migraine and CVD Risk in Women

NCT03081390
View directory record Official record
Conditions
Migraine
Interventions
Mixed meal tolerance testing, Skin conductance & cold pressor test, Flow-mediated dilation testing
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 8:01 PM EDT